GU Cancers 2024 | Management of urothelial carcinoma with positive pelvic/retroperitoneal lymph nodes

Monika Joshi, MD, Penn State Cancer Institute, Hershey, PA, discusses treatment options for patients with urothelial carcinoma and positive pelvic or retroperitoneal lymph nodes, who have achieved complete response. Dr Joshi highlights the role of systemic therapy in node positive urothelial carcinoma, as well as biomarkers such as circulating tumor DNA (ctDNA), tumor mutational burden (TMB) and PD-L1. This interview took place at the ASCO GU Cancers Symposium 2024 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.